Kanwal Raghav

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (11)

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jason Willis

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jonathan M. Loree

The University of British Columbia

CANADA

View details

Christine Parseghian

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Sarina Piha-Paul

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ian Chau

Royal Marsden Hospital Sutton

UNITED KINGDOM

View details

Mark Moasser

Professor

University of California, San Francisco

UNITED STATES

View details

Van Karlyle Morris

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Won Jin Ho

Johns Hopkins University School of Medicine

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Benny Johnson

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kanwal Raghav

Research Interests

Explore related searches

Contact this professor

Articles (19)

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT

Cancer of Unknown Primary Site

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Molecular Pathways and Mechanisms of HER2 in Cancer Therapy

Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy

Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors

Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)

Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Reply to Y. Yu et al

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience

Collaborators (11)

Scott E. Kopetz

Jason Willis

Jonathan M. Loree

Christine Parseghian

Sarina Piha-Paul

Ian Chau

Mark Moasser

Van Karlyle Morris

Won Jin Ho

Timothy Yap

Benny Johnson

Make your next move.